Free Trial
OTCMKTS:BVNRY

Bavarian Nordic 3/5/2025 Earnings Report

Bavarian Nordic logo
$12.32 -0.01 (-0.08%)
As of 08/29/2025 03:38 PM Eastern

Bavarian Nordic EPS Results

Actual EPS
$0.47
Consensus EPS
$0.40
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Bavarian Nordic Revenue Results

Actual Revenue
$299.48 million
Expected Revenue
$264.06 million
Beat/Miss
Beat by +$35.42 million
YoY Revenue Growth
N/A

Bavarian Nordic Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bavarian Nordic's next earnings date is estimated for Friday, November 14, 2025, based on past reporting schedules.

Conference Call Resources

Bavarian Nordic Earnings Headlines

Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
Q2 2025 Bavarian Nordic A/S Earnings Call Transcript
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

View Bavarian Nordic Profile

More Earnings Resources from MarketBeat